Immix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201 Immix Biopharma (IMMX) said Monday the first patient has been dosed in a US trial of AL amyloidosis with NXC-201.The trial ...
Source LinkImmix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201 Immix Biopharma (IMMX) said Monday the first patient has been dosed in a US trial of AL amyloidosis with NXC-201.The trial ...
Source Link
Comments